Literature DB >> 2962418

Ovulation inhibition with 17 beta-estradiol cyclo-octyl acetate and desogestrel.

W Schubert1, G Cullberg.   

Abstract

Ovulation inhibition and bleeding control with a combination of 0.5 mg 17 beta-estradiol cyclo-octyl acetate (E2COA) and 0.15 mg desogestrel was investigated in 10 regularly menstruating women for 21 days. In half the group the treatment was extended for 7 days (days 22-28) with 0.03 mg desogestrel in order to evaluate any posttreatment influence on the gonadotropin levels. E2COA, beeing a long-chain fatty ester dissolved in oil, was expected to be resorbed from the intestinal wall via the lymphatic system. By incorporating it in the chylomicrons, E2COA would thereby avoid the unfavourable first liver pass. The serum levels of progesterone were suppressed during treatment. No increase in 17 beta-estradiol (E2) concentration was found; levels remained low and even during medication. No peak values of gonadotropins were seen. Thus follicular hormonal activity and ovulation was inhibited by this combination. Bleeding control was, however unacceptable in all volunteers. The addition of desogestrel during the fourth investigation week apparently did not induce any hormonal differences. The estrogenic activity is shown by the low, even S-E2 levels, but the dosage of E2COA seems to be too low in relation to progestogen dosage. Further studies will have to be performed in order to find the ideal combination.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2962418     DOI: 10.3109/00016348709015732

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  6 in total

1.  Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study.

Authors:  Wolfgang Junge; Uwe Mellinger; Susanne Parke; Marco Serrani
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Pharmacokinetic evaluation of oral 17 beta-oestradiol and two different fat soluble analogues in ovariectomized women.

Authors:  W Schubert; G Cullberg; T Hedner
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

3.  Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill.

Authors:  Maurizio Guida; Giuseppe Bifulco; Attilio Di Spiezio Sardo; Mariamaddalena Scala; Loredana Maria Sosa Fernandez; Carmine Nappi
Journal:  Int J Womens Health       Date:  2010-08-24

4.  Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel.

Authors:  Christine Klipping; Ingrid Duijkers; Susanne Parke; Uwe Mellinger; Marco Serrani; Wolfgang Junge
Journal:  Drugs R D       Date:  2011

5.  Endometrial safety of an oral contraceptive containing estradiol valerate and dienogest.

Authors:  Johannes Bitzer; Susanne Parke; Thomas Roemer; Marco Serrani
Journal:  Int J Womens Health       Date:  2011-04-18

Review 6.  An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest.

Authors:  Franca Fruzzetti; Florence Trémollieres; Johannes Bitzer
Journal:  Gynecol Endocrinol       Date:  2012-04-02       Impact factor: 2.260

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.